Tesamorelin Ipamorelin Blend 10mg/3mg | Research Use Only

Tesamorelin/Ipamorelin

The Tesamorelin Ipamorelin blend is a lyophilized research peptide combination supplied by NuScience Peptides strictly for laboratory use. Each vial contains Tesamorelin (10mg), a GHRH analog, and Ipamorelin (3mg), a selective GHS-R1a agonist. Purity: 99%+. Lab tested. Not for human consumption..

Combining tesamorelin/ipamorelin in rat studies offers a promising avenue for investigating the synergistic effects of growth hormone-releasing agents on various physiological processes. Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, has been shown to significantly reduce visceral adipose tissue and improve liver health by decreasing liver fat and preventing fibrosis progression. Ipamorelin, a selective growth hormone secretagogue, has demonstrated efficacy in stimulating growth hormone (GH) release, leading to increased longitudinal bone growth and enhanced bone mineral content in rats.

In a study by Johansen et al., ipamorelin administration in rats resulted in a dose-dependent increase in longitudinal bone growth, attributed to its potent GH-releasing properties. Similarly, research has indicated that ipamorelin can counteract glucocorticoid-induced reductions in bone formation, suggesting its potential in mitigating bone density loss associated with glucocorticoid therapy.

Tesamorelin’s impact on liver health was highlighted in a study where it significantly reduced liver fat and prevented fibrosis progression over a year-long period.  These findings underscore tesamorelin’s potential therapeutic role in managing conditions characterized by excessive visceral fat and liver steatosis.

Combining these peptides in rat models may provide insights into their collective effects on body composition, bone density, and metabolic health. While individual studies have demonstrated the benefits of tesamorelin and ipamorelin separately, research on their combined administration is limited. Further investigations are warranted to elucidate the potential synergistic effects and safety profiles of this combination.

How the Tesamorelin Ipamorelin Blend Works in Research Models

The Tesamorelin Ipamorelin blend targets the growth hormone axis through two distinct receptor mechanisms, making it a widely studied dual-action combination in peptide research.

Tesamorelin is a synthetic GHRH analog that binds to GHRH receptors on pituitary somatotrophs, stimulating the cAMP/PKA signaling cascade and triggering pulsatile growth hormone secretion. It has been shown in research to increase total GH levels by approximately 69%, measured via AUC, alongside elevated IGF-1 production.

Ipamorelin is a selective GHS-R1a agonist that activates ghrelin receptors in the pituitary and hypothalamus. Unlike other GH secretagogues, ipamorelin is noted for its high receptor selectivity and does not significantly affect cortisol or ACTH release. Its proposed mechanism involves phospholipase C activation, calcium ion release, and subsequent GH vesicle exocytosis.

When combined, the two peptides activate the growth hormone axis at different receptor sites simultaneously, which preclinical research suggests may produce a synergistic effect on GH output beyond what either peptide achieves individually.

Dual-Mechanism GH Axis Activation

Handling, Reconstitution and Storage

• Store the lyophilized vial at -20C until use
• Reconstitute with bacteriostatic water (BAC water) or sterile water using aseptic technique
• To calculate the exact BAC water volume for your target concentration, use the NuScience Peptide Calculator
• Once reconstituted, store at 4C and use within the research protocol window
• For comprehensive storage protocols, see the NuScience Peptide Handling and Storage guide
• Do not freeze after reconstitution
• This product is for laboratory research use only. Not for human or veterinary use.

Lab Testing Section

Every batch of the Tesamorelin Ipamorelin blend supplied by NuScience Peptides undergoes third-party laboratory testing to verify peptide identity and purity. Certificates of Analysis are available on the NuScience Lab Test Results page. Accurate research depends on verified compounds.

References:

Johansen, P. B., et al. “Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Longitudinal Bone Growth in Rats.” Growth Hormone & IGF Research, vol. 9, no. 2, Apr. 1999, pp. 106–113. https://pubmed.ncbi.nlm.nih.gov/10373343/.

Svensson, J., et al. “The GH Secretagogues Ipamorelin and GH-Releasing Peptide-6 Increase Bone Mineral Content in Adult Female Rats.” Journal of Endocrinology, vol. 165, no. 3, June 2000, pp. 569–577. https://joe.bioscientifica.com/view/journals/joe/165/3/569.xml.

Stanley, T. L., et al. “Effects of Tesamorelin on Hepatic Transcriptomic Signatures in HIV-Associated NAFLD.” The Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 10, Oct. 2020, pp. 745–5119. https://pmc.ncbi.nlm.nih.gov/articles/PMC7455119/.